Search results
Results from the WOW.Com Content Network
All seven relaxin family peptide hormones are synthesized as pre-prohormones, and subsequently cleaved to form two chains stabilized by an intra-α-chain and two disulfide bonds. [5] Members of the human relaxin peptide family share a similar tertiary structure , composed of a β-chain, c-chain, and α-chain at their carboxyl-terminal .
Relaxin is a protein hormone of about 6000 Da, [1] first described in 1926 by Frederick Hisaw. [2] [3]The relaxin family peptide hormones belong to the insulin superfamily and consists of seven peptides of high structural but low sequence similarity; relaxin-1 (RLN1), 2 (RLN2) and 3 (), and the insulin-like (INSL) peptides, INSL3, INSL4, INSL5 and INSL6.
The insulin/IGF/relaxin family is a group of evolutionary related proteins which possess a variety of hormonal activities. [1] Family members in human include two subfamilies: 1) insulin and insulin-like growth factors [2] 2) relaxin family peptides: relaxins 1 and 2; relaxin 3; Leydig cell-specific insulin-like peptide (gene INSL3) [3]
Relaxin/insulin-like family peptide receptor 1, also known as RXFP1, is a human G protein coupled receptor that is one of the relaxin receptors. [5] It is a rhodopsin-like GPCR which is unusual in this class as it contains a large extracellular binding and signalling domain. [6]
The relaxin receptors are a subclass of four closely related G protein-coupled receptors (GPCR) that bind relaxin peptide hormones. [ 1 ] [ 2 ] Below is list of human relaxin receptors, their endogenous peptide hormones, and what downstream enzymes are activated or inhibited by the receptor.
The cognate receptor for relaxin-3 is the G-protein coupled receptor RXFP3 (relaxin family peptide 3 receptor), however relaxin-3 is pharmacologically able to also cross react with RXFP1 and RXFP3 (although the physiological relevance of such interactions, if they exist endogenously, are currently unknown).
Relaxin causes vasodilation by an indirect mechanism, where it inhibits the potent vasoconstrictors angiotensin II and endothelin. [9] In addition to vasodilation, the effects of relaxin are also seen in the kidneys, by significantly increasing creatinine clearance, [ 10 ] which is a measure of kidney function, as well as increased renal blood ...
Volenrelaxin (LY3540378) is a long-acting, synthetic analogue of relaxin developed by Eli Lilly and Company to treat heart failure. [1] [2] References